Pulmonary Arterial Hypertension Treatment Market By by Drug Type (Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global pulmonary arterial hypertension treatment market was valued at $7,177.81 million in 2021, and is projected to reach $11,968.60 million by 2031, registering a CAGR of 5.2% from 2022 to 2031.
Pulmonary Arterial Hypertension (PAH) is a medical condition defined as the endothelial dysfunction and vascular remodeling block the tiny pulmonary arteries, increasing pulmonary vascular resistance and pulmonary pressures which results in reduced cardiac output, right heart failure and finally death of the patient. Pulmonary arterial infection can occur due to number of conditions, including those that are transferred through generations, like connective tissue disease, HIV infection, portal hypertension (liver disease), sickle cell disease, and congenital heart disease. The symptoms associated with pulmonary arterial hypertension are blue lips and skin (cyanosis), chest pressure or pain, dizziness, weariness, shortness of breath (dyspnea) while exercising, and or at rest. The drugs such as sildenafil (revatio, viagra) and tadalafil (adcirca) are used to treat patients with pulmonary arterial hypertension.
The key factors that drive the growth of pulmonary arterial hypertension treatment market are increase in the prevalence of geriatric population affected with pulmonary arterial hypertension; rise in prevalence of HIV cases and surge in healthcare expenditure boost the market growth. According to National Center for Biotechnology Information in 2020, reported that the patient with HIV positive having risk of 0.5% higher prevalence of pulmonary arterial hypertension (PAH) than HIV-negative individuals with a difference of around 2500 times.
In addition, according to data from an article in the Cardiovascular Diagnosis and Therapy Journal published in 2020, (which discusses the global epidemiology of pulmonary hypertension with a focus on sub-Saharan Africa and low- and middle-income countries), it is estimated that 80% of patients with pulmonary hypertension below age group 65, who have a high risk of congenital heart disease, rheumatic heart disease, and HIV, live in low and middle-income countries.
In addition, rise in number of product approvals and key strategic developments by regulatory authorities for effective treatment of pulmonary artery hypertension contribute toward market growth. For instance, Janssen Pharmaceutical Companies of Johnson & Johnson, is a one of the key players involved in manufacturing and development of drugs for pulmonary arterial hypertension. It has announced the submission of product approval application to FDA for the use of UPTRAVI product intravenously to cure the patient with pulmonary artery hypertension. However, side effects associated with drug based pulmonary arterial hypertension treatment restricts the market growth during forecast period. Moreover, rise in growth potential in developing countries offers lucrative opportunities to market players operating in the pulmonary arterial hypertension treatment market.
The pulmonary arterial hypertension treatment market is segmented into drug type, type, route of administration and region. On the basis of drug type, the market is categorized into endothelin receptor antagonists (ERAs), PDE-5 inhibitors, prostacyclin, and prostacyclin analogs and sGC stimulators. On the basis of type, it is further bifurcated into branded and generic. The branded segment is further classified into retail pharmacy, hospital pharmacy and online pharmacy. The generic segment is further classified into retail pharmacy, hospital pharmacy and online pharmacy. On the basis of route of administration, the market is further classified into oral, intravenous/ subcutaneous, and inhalational. On the basis of region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global pulmonary arterial hypertension treatment market are Bayer AG, GlaxoSmithKline Plc, Gilead Sciences, Inc., Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation and Viatris Inc.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the pulmonary arterial hypertension treatment market analysis from 2021 to 2031 to identify the prevailing pulmonary arterial hypertension treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the pulmonary arterial hypertension treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global pulmonary arterial hypertension treatment market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By by Drug Type
Endothelin Receptor Antagonists (ERAs)
Prostacyclin and Prostacyclin Analogs
By Route of Administration
Rest Of Europe
Rest Of Asia-Pacific
Rest Of LAMEA
Key Market Players
United Therapeutics Corporation
Gilead Sciences, Inc.
Johnson & Johnson
Lupin Pharmaceuticals, Inc.
Sun Pharmaceutical Industries, Inc.
Teva Pharmaceutical Industries Ltd.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook